Survey on Discovering New Therapeutic Uses for Existing Molecules

Working in conjunction with NCATS, we want to understand the life sciences community’s opinion about the recently launched drug repositioning pilot program – Discovering New Therapeutic Uses for Existing Molecules – spearheaded by NIH’s translational sciences department. Compete the survey now – it will only take a few minute of your time! This brief survey will be used to help …

Academia’s role in drug repositioning: an interview with Dr. S Joshua Swamidass

Dr. S Joshua Swamidass, Assistant Professor, Washington University School of Medicine, took the time to speak with us on the role of academia in the multi-stakeholder collaboration initiatives towards drug repositioning. Download the interview here > We asked Joshua several questions about academia’s role in drug repositioning including: What is the key difference in the way academia and industry approach …

Literature mining in support of drug discovery

The drug discovery enterprise provides strong drivers for data integration.While attention in this arena has tended to focus on integration of primary data from omics and other large platform technologies contributing to drug discovery and development, the scientific literature remains a major source of information valuable to pharmaceutical enterprises, and therefore tools for mining such data and integrating it with …

Systematic drug repositioning based on clinical side-effects – whitepaper from Pankaj Agarwal

Pankaj Agarwal, Director, Systematic Drug Repositioning, Computational Biology, GlaxoSmithKline kindly provided this whitepaper on the topic, ‘Systematic Drug Repositioning Based on Clinical Side-Effects.‘ In the paper, Lun Yang and Pankaj Agarwal suggest that drug “repositioning helps fully explore the indications of marketed drugs and clinical candidates; however, most successful stories of repositioning are based on serendipity and not systematic analysis.” …